• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

    11/12/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email

    SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.*

    In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP and SST were thoroughly examined.

    All 14 peptides were influenced in the desired direction, with key results including: *†††

    • GRP (gastrin-releasing peptide responsible for sending alerts to fire up digestion): +1,087% increase*†††
    • TFF3 (trefoil factor 3 which manages gut lining repair): +116% increase*†††
    • VIP (vasoactive intestinal peptide which helps to calm overactive areas of the gut): +100% increase*†††
    • OXM (oxyntomodulin which coordinates nutrient absorption): +77% increase*†††
    • CCK (cholecystokinin which ensures fats and proteins are properly processed): +69% increase*†††

    "These findings demonstrate that our proprietary P84 blend has a remarkable impact on activating key processes at the cellular level," said Lisa Barnes, Vice President of R&D and Regulatory at LifeVantage. "P84 reinforces LifeVantage's position at the forefront of nutrigenomic innovation by positively influencing key markers necessary to ensure a strong, healthy gut. Gut health is at the root of so many things that impact people of all ages. It's incredibly exciting to offer products that are unlike anything else, deliver meaningful change and create a lasting impact for consumers." *

    In vitro research supports scientists in their understanding of how nutrients and bioactive compounds interact with cells in a controlled environment. Typically, biomarker changes of 20-30% are considered biologically meaningful, and in these studies, P84 exceeded those thresholds across multiple targets.

    The next phase of this important research will include mRNA sequencing analysis of the P84 blend in combination with the company's Protandim® Nrf2 Synergizer® and MindBody GLP-1 System™ formulas.

    LifeVantage brought P84 into its activating product portfolio after acquiring the critical assets of LoveBiome, a direct sales company centered on gut and microbiome health, in October 2025. P84 helps create the right environment for beneficial bacteria to thrive, restoring calm, balance and strength to your body's "second brain". It's offered along with Protandim Nrf2 Synergizer as part of the Healthy Edge Stack, which helps consumers get the proactive edge on their health through cellular activation.*

    To learn more about the science behind P84 and other LifeVantage products, visit www.lifevantage.com.

    About LifeVantage Corporation

    LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and the comprehensive gut activator, P84. The robust portfolio also includes activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*

    Investor Relations Contact:

    Reed Anderson, ICR

    (646) 277-1260

    [email protected]

    Public Relations Contact:

    CerconeBrownCompany

    [email protected]

    *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    †††Results based on a cell culture study on P84.  



    Primary Logo

    Get the next $LFVN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    SEC Filings

    View All

    Lifevantage Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Lifevantage Corp (0000849146) (Filer)

    11/12/25 4:35:42 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    11/4/25 4:06:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lifevantage Corporation

    10-Q - Lifevantage Corp (0000849146) (Filer)

    11/4/25 4:05:03 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewis Darwin bought $4,882 worth of shares (450 units at $10.85), increasing direct ownership by 0.39% to 117,217 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/18/25 4:36:17 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    6/17/25 4:11:27 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    5/13/25 4:11:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anbalagan Rajendran was granted 13,531 shares, increasing direct ownership by 129% to 23,999 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:15:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Latham Cynthia was granted 13,531 shares, increasing direct ownership by 26% to 64,879 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:15:07 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Greer Raymond B was granted 13,531 shares, increasing direct ownership by 14% to 112,819 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:14:59 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

    SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.* In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP an

    11/12/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod

    11/4/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an increase of 0.7% from the prior year period. Excluding the impact of foreign currency fluctuations, first quarter revenue increased approximately 0.3%;Revenue in the Americas increased 0.8%, and revenue in Asia/Pacific & Europe increased 0.4%.  Excluding the foreign currency fluctuations, first quarter revenue in Asia/Pacific & Eu

    11/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Financials

    Live finance-specific insights

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod

    11/4/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an increase of 0.7% from the prior year period. Excluding the impact of foreign currency fluctuations, first quarter revenue increased approximately 0.3%;Revenue in the Americas increased 0.8%, and revenue in Asia/Pacific & Europe increased 0.4%.  Excluding the foreign currency fluctuations, first quarter revenue in Asia/Pacific & Eu

    11/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce First Quarter Fiscal Year 2026 Results on November 4, 2025

    SALT LAKE CITY, Oct. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2025, after the stock market closes on Tuesday, November 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours

    10/21/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

    SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

    1/16/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

    SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever

    8/26/24 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care